peldesine

Peldesine is a small molecule purine nucleoside phosphorylase (PNP) inhibitor developed by BioCryst Pharmaceuticals. It acts as an immunosuppressant and antineoplastic agent by selectively inhibiting PNP, an enzyme required for T-cell replication. Inhibition of PNP leads to the accumulation of deoxyguanosine triphosphate (dGTP), resulting in impaired DNA synthesis and suppression of T-cell proliferation. Peldesine was investigated for the treatment of various T-cell mediated diseases including psoriasis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, transplant rejection, cutaneous T-cell lymphoma, leukemia, HIV infections, and eye disorders. Despite reaching phase II/III clinical trials in some indications (notably as a topical therapy for cutaneous T-cell lymphoma), all development programs were discontinued due to lack of significant efficacy over placebo[1][2][3][7].

Other names

Peldesina133432-71-0